15th Lipid and Atherosclerosis Forum

From Bench to Bedside: Recent advances in Lipoproteins, Cardiometabolic Disorders and Atherosclerosis Translated to a Better Patient Care

Monday, 7th December 2026
(Day 1)
12:00 Lunch and registration
12:50 Welcome and introduction Prof Handrean Soran
13:00 Session 1: Homozygous Familial Hypercholesterolaemia: Contemporary
Challenges and Emerging Solutions.		 Chairs: Dr Paul Flynn and Dr Hannah Delaney
13:10 An overview of HoFH and Can we Achieve LDL-C Targets With New Treatment
Options		 Professor Dirk Blom, South Africa.
13:30 Real World Experience with Evinacumab in Children. Dr Michael Champion, UK
13:50 Service Quality Status and unmet clinical needs of HoFH and what Lomitapide
added: Data from UK project and HoFH register.		 Dr Charlotte Dawson, UK
14:10 Sitosterolaemia: A review, differential diagnoses and a call for action. Dr Bilal Bashir, UK.
14:30 Panel Discussion
14:50 Coffee Break
15:10 Session 2: Severe Hypertriglyceridaemia: Advances in Diagnosis, Treatment
and Patient Care.		 Chairs: Gilles Lambert and TBC
15:15 Severe Hypertriglyceridaemia: Insights from the national Spanish registry, Genetics and Clinical presentations. Dr. María José Ariza, Spain
15:35 Rethinking Dysbetalipoproteinaemia: Can we identify and manage better to improve outcomes? Dr Ahai Luvai, UK
15:55 Lipid management during pregnancy and post-partum: consensus statement from Heart UK and MOMS. Prof Jaimini Cegla, UK
16:15 Short presentations
16:20 HoFH or not? Professor Dirk Blom, South Africa
16:30 Managing FCS Through Pregnancy: Insights Into Volanesorsen Exposure and Safety. Dr Paul Downie, UK
16:40 Statin-Induced Autoimmune Myositis: A Lipid Management Case Series. Dr Fiona Jenkinson, UK
16:50 Panel discussion
17:25 Close
18:30 Coaches leave for Speaker and Chairs Dinner
22:00 Return to hotel



Tuesday, 8th December 2026
(Day 2)
08:30 Coffee/Tea and registration.
08:55 Welcome and Introduction Prof Handrean Soran
09:00 Session 3: Identifying and Managing Cardiometabolic Risk Factors. Chairs: TBC
09:05 CVD Prevent: Turning Data into Better Outcome. Dr Pete Green, Chair of Trustees of HEART UK, UK
09:25 MASLD and cardiovascular risk: What do we need to know? Professor Christopher Byrne, UK
09:45 Lipids and Microvascular Complications: What Do We Know and What is New? Dr Maryam Ferdousi, UK
10:05 CKD and ASCVD: The Real Risk and How to Address it? Professor Winfried März, Germany
10:25 Panel Disccussion.
10:45 Coffee Break
11:15 Session 4: Precision Lipidology for Cardiovascular Risk Reduction Chairs: Dr Kissmat Mirkhan
11:20 Lipoprotein (a) as a cardiovascular risk and what we have learnt from lipoprotein
apheresis and vascular studies.		 Dr Tina Khan, UK
11:40 Lipoprotein (a) Lowering: An Overview of Phase 3 Clinical Trials and HORIZON Study Result. Professor Ioanna Gouni-Berthold, Germany
12:00 Lipid-Lowering Therapy in older patients. Professor Anthony Wierzbicki, UK
12:20 Lipids and Outcomes - Insights from CPRD. Professor. Riyaz Patel, UK
12:40 Managing Cardiovascular Risk in Patients with Hypertriglyceridameia: What HEART UK Statement Recommends? TBC
13:00 Panel Discussion
13:20 Lunch
14:15 Session 5: The evolving landscape of cardiovascular risk: Assessment, Prevention and Management. Chairs: Dr Shazli Azmi and TBC
14:20 The Immune System and Lipids: When Biology Goes to Extremes and how to
address?		 Professor Dirk Blom, South Africa
14:40 CT Coronary Angiogram as a predictor of cardiovascular events and how to interpret
and integrate reports to optimise patients care?		 TBC
15:00 Obesity and associated morbidities: Current and future medical approaches. Professor Dev Datta, UK.
15:20 The Latest in CVD risk management in Type 1 & Type 2 Diabetes Management,
NICE CGs and Technology Appraisals.		 Dr Jonathan Schofield, UK.
15:40 Short Presentations
15:40 CTCA Audit Dr Adam Darnley, UK.
15:55 Chylomicronaemia Syndrome International Project. Dr Atiqah Sapiyan, UK
16:10 TBC TBC
16:20 Panel discussion
16:45 Closing remarks and feedback Prof Handrean Soran



Sponsors to be confirmed